Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype

A. L. de Groen, Ronald van Eijk, Stefan Bohringer, Tom van Wezel, Richard Raghoo, Dina Ruano, Patty M. Jansen, Inge Briaire-De Bruijn, Fleur A. de Groot, Karin Kleiverda, Liane te Boome, Valeska Terpstra, Henriette Levenga, Alina Nicolae, Eduardus F.M. Posthuma, Isabelle Focke-Snieders, Lizan Hardi, Wietske C.E. den Hartog, Lara H. Bohmer, Pancras C.W. HogendoornAnke van den Berg, Arjan Diepstra, Marcel Nijland, Pieternella J. Lugtenburg, Marie Jose Kersten, Steven T. Pals, Hendrik Veelken, Judith V.M.G. Bovee, Arjen H.G. Cleven, Joost S.P. Vermaat*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

17 Citations (Scopus)
14 Downloads (Pure)
Original languageEnglish
Pages (from-to)3760-3775
Number of pages16
JournalBlood advances
Issue number19
Publication statusPublished - 12 Oct 2021

Bibliographical note

Funding Information:
This study is funded by the Stichting Fonds Oncologie Holland.

Funding Information:
Conflict-of-interest disclosure: M.J.K. has received honoraria/ research funding from Kite Pharma, Millennium/Takeda, Mundi-pharma, Gilead Sciences, Bristol Myers Squibb, Roche, Celgene, Novartis Pharmaceuticals Corporation, and Amgen. P.J.L. has received honoraria/research funding from Takeda, Servier, Genmab, Roche, Genentech, Celgene, Incyte, and Regeneron. The remaining authors declare no competing financial interests.

Cite this